Navigation Links
Senetek PLC Announces Debut of Pyratine-6(TM) at the Annual Meeting of the American Academy of Dermatology
Date:2/5/2008

NAPA, Calif., Feb. 5 /PRNewswire-FirstCall/ -- Senetek PLC (OTC Bulletin Board: SNKTY), a Life Sciences company engaged in the development of technologies that target the science of healthy aging, today announced the debut of Pyratine-6(TM) at the 66th Annual Meeting of the American Academy of Dermatology in San Antonio, Texas.

Pyratine-6(TM), Senetek's exclusive second generation cytokinin, has been clinically proven to be effective in correcting visible signs of skin aging and significantly reducing erythema as early as two weeks from onset of use.

The Annual Meeting of the American Academy of Dermatology runs from February 1 - 5, 2008. Approximately 7,000 medical personnel are registered to attend.

Commenting on the debut, Mr. Frank Massino, Senetek's Chairman and Chief Executive Officer stated, "We are delighted to see this compelling therapeutic come to the market and are very pleased by the reception Pyratine-6(TM) has received from dermatologists at this important conference. Pyratine-6(TM) has been successfully clinically tested and has shown attributes more beneficial to treatment than any predecessor compound."

About Senetek PLC

Senetek PLC (OTC Bulletin Board: SNKTY) is a Life Sciences company engaged in the development of breakthrough technologies that target the science of healthy aging. The Company's extensive research collaborations have resulted in a strong pipeline of patented compounds and products with broad therapeutic applications and a leading presence in dermatology. Senetek collaborates with established specialty pharmaceutical companies in the final development and marketing of its proprietary products, most recently resulting in the development of the best-selling anti-aging product sold in the North American physician market.

For more information, visit the company's website at http://www.senetekplc.com.

This news release contains statements that may be considered 'forward-looking statements' within the meaning of the Private Securities Litigation Reform Act. Forward-looking statements by their nature involve substantial uncertainty, and actual results may differ materially from those that might be suggested by such statements. Important factors identified by the Company that it believes could result in such material differences are described in the Company's Annual Report on Form 10-K for the year 2006. However, the Company necessarily can give no assurance that it has identified or will identify all of the factors that may result in any particular forward-looking statement materially differing from actual results, and the Company assumes no obligation to correct or update any forward-looking statements which may prove to be inaccurate, whether as a result of new information, future events or otherwise.


'/>"/>
SOURCE Senetek PLC
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Senetek PLC Reports Third Quarter 2007 Financial Results
2. Coherent Announces Director Slate for Upcoming Annual Meeting
3. MAP Pharmaceuticals Announces Resignation of Chief Medical Officer
4. CorVel Announces Record Earnings Per Share
5. Better Nutrition Announces Best Of Beauty Awards Winners Showcasing the Best Natural Beauty Products of 2008
6. Naviscan Announces a New Chairman and Board Member
7. Globus Medical Announces Record Revenue for 2007
8. HealthFitness Announces Executive Changes: Chief Operations Officer And New Medical Officer Appointed; Vice Chairman Retires
9. Sharps Compliance Corp. Announces 20% Growth in Customer Billings for Second Quarter of Fiscal Year 2008
10. Sergeants(R) Pet Care Products Announces Cause Marketing Partnership With the National Wildlife Federation
11. Poniard Pharmaceuticals Announces Upcoming Conference Participation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... , ... June 26, 2016 , ... Brent Kasmer, a legally blind and certified personal ... personalized through a fitness app. The fitness app plans to fix the two major problems ... offer a one size fits all type program , They don’t eliminate all ...
(Date:6/25/2016)... ... June 25, 2016 , ... The temporary closing of Bruton Memorial Library on June ... , brings up a new, often overlooked aspect of head lice: the parasite’s ability to ... is not a common occurrence, but a necessary one in the event that lice have ...
(Date:6/25/2016)... Oklahoma City, Oklahoma (PRWEB) , ... June 25, ... ... to helping both athletes and non-athletes recover from injury. Recently, he has implemented ... for the Oklahoma City area —Johnson is one of the first doctors to ...
(Date:6/24/2016)... ... ... Those who have experienced traumatic events may suffer from a complex set of ... or alcohol abuse, as a coping mechanism. To avoid this pain and suffering, Serenity ... event. , Trauma sufferers tend to feel a range of emotions, from depression, guilt, ...
(Date:6/24/2016)... ... ... Global law firm Greenberg Traurig, P.A. announced that 20 Florida attorneys are recognized ... this recognition are considered among the top 2 percent of lawyers practicing within the ... this year’s Legal Elite Hall of Fame: Miami Shareholders Mark D. Bloom, Burt ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... -- Any dentist who has made an implant supported denture ... of them do not even offer this as a viable ... costs involved. And those who ARE able to offer that ... cost that the majority of today,s patients would not be ... , founder of Dental Evolutions Inc. and inventor of Implanova ...
(Date:6/23/2016)... Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that it ... (procalcitonin) assay as a dedicated testing solution for people ... Roche is the first IVD company in the U.S ... assessment and management. PCT is a sepsis-specific ... blood can aid clinicians in assessing the risk of ...
(Date:6/23/2016)... 2016 Research and Markets has announced ... report to their offering. ... a favourable commercial environment for MedImmune to enter. The US ... will serve to drive considerable growth for effective anti-influenza medications. ... cap sales considerably, but development is still in its infancy. ...
Breaking Medicine Technology: